Boston Scientific Co. (NYSE:BSX)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $39.13 and last traded at $38.91, with a volume of 256291 shares traded. The stock had previously closed at $38.83.

A number of research firms recently issued reports on BSX. Morgan Stanley upped their price target on shares of Boston Scientific from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. Piper Jaffray Companies upped their price target on shares of Boston Scientific to $38.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. Jefferies Financial Group reaffirmed a “hold” rating and set a $34.00 price target on shares of Boston Scientific in a research note on Thursday, July 26th. Stifel Nicolaus reaffirmed a “buy” rating and set a $37.00 price target on shares of Boston Scientific in a research note on Thursday, July 26th. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating on shares of Boston Scientific in a research note on Friday, July 6th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company. Boston Scientific has an average rating of “Buy” and an average price target of $36.43.

The company has a current ratio of 0.83, a quick ratio of 0.60 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $53.39 billion, a P/E ratio of 30.45, a PEG ratio of 2.68 and a beta of 0.63.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.07. The firm had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.32 earnings per share. equities analysts forecast that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

In other news, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $32.42, for a total value of $162,100.00. Following the sale, the executive vice president now directly owns 29,201 shares in the company, valued at approximately $946,696.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jeffrey B. Mirviss sold 33,512 shares of the firm’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $34.00, for a total transaction of $1,139,408.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 212,680 shares of company stock worth $7,619,335. 0.73% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in BSX. Royal London Asset Management Ltd. purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $18,832,000. WCM Investment Management CA raised its position in shares of Boston Scientific by 19.6% in the 2nd quarter. WCM Investment Management CA now owns 3,367,217 shares of the medical equipment provider’s stock valued at $110,108,000 after purchasing an additional 551,403 shares during the last quarter. LFA Lugano Financial Advisors SA purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $715,000. Public Employees Retirement System of Ohio raised its position in shares of Boston Scientific by 2.0% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 965,855 shares of the medical equipment provider’s stock valued at $31,583,000 after purchasing an additional 19,383 shares during the last quarter. Finally, WealthPLAN Partners LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $208,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Boston Scientific (NYSE:BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: How a Put Option Works

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.